EUCTR2006-003508-21-FR进行中（未招募）不适用
A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 548
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Outpatients of either sex and 12 – 75 years of age.
- •2. Clinically suspected dermatophyte infection confirmed by a positive KOH microscopy and culture performed by the central mycology laboratory.
- •3. The target toenail area must have at least 25% to no more than 75% disease involvement without spikes.
- •4. At least 1 large (great) toenail meeting the infection criteria. (If more than 1 large toenail is infected and meets inclusion/exclusion criteria, both toenails should be sampled for culture. The toenail with greater involvement will be selected as the target nail. If both large toenails have the same degree of involvement, the right toenail will be selected as the target” toenail.
- •5. The target large toenail must be confirmed as having at least a minimum of 1 mm growth, measured by the site, within the 4-6 week screening period.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients who have had systemic antifungal therapy within 6 months prior to screening for the study.
- •2. Patients who have used prescription topical antifungal therapy indicated for onychomycosis within 3 months prior to screening, or commercially available topical antifungal therapy for onychomycosis or any other commercially available topical antifungal therapy applied directly to the toenails within 1 month prior to screening.
- •3. Patients who have used other investigational drugs at the time of enrollment or within 30 days.
- •4. Nail infection due to an organism other than a dermatophyte (mixed infections [dermatophyte and non-dermatophyte] are not allowed).
- •5. The target foot has severe plantar (moccasin) tinea pedis infection that would require systemic therapy (as determined by the investigator). Mild to moderate tinea pedis infection should be treated with Lamisil DermGel, or with Lamisil Cream if Lamisil DermGel is unavailable, to eliminate fungal reservoir as needed prior to baseline or at any time during the trial. Other topical treatments indicated for tinea pedis may be recommended at the discretion of the investigator.
- •6. Patients with the target toenail involving the matrix (lunula) or having less than 2mm clear (unaffected) nail plate length beyond the proximal fold.
- •7. Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail.
- •8. Patients with abnormalities of the target nail that could prevent obtaining a normal appearing nail if clearing of the infection is achieved (i.e. tumors, chemical damage, genetic disorders, pigmentary disorders, psoriasis, collagen vascular disease, lichen planus, peripheral vascular disease, traumatic onychodystrophy due to chronic stimuli, structural deformity, severe diabetic foot neuropathy).
- •9. Patients with abnormal findings (laboratory or physical) or conditions which are considered to be clinically important by the investigator and indicative of conditions that could jeopardize patient safety or interfere with the interpretation of the results of the study. Please note: diabetic patients may be enrolled in the study if their diabetes is well-controlled.
- •10. Patients with a history of malignancy of any organ system within the past year, whether or not there is recurrence or metastases, with the exception of localized basal cell or squamous cell carcinoma of the skin for which medical intervention should be planned.
- •11. Known pregnant or lactating women at the time of enrollment or patients who plan to become pregnant during the study period.
- •12. Patients with sensitivity to terbinafine or excipients of the formulation.
- •13. Patients not likely or unable to cooperate with study requirements including those with a recent history of alcohol or drug abuse, or are currently known to abuse alcohol or drugs.
- •14. Patients not willing to stop professional pedicures, or not willing to remove or discontinue the use of any nail polish product or other nail cosmetic product on their toenails at the screening visit and throughout the study.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosisOnychomycosis (mild to moderate)MedDRA version: 8.1Level: LLTClassification code 10030338Term: OnychomycosisEUCTR2006-003508-21-DEovartis Pharma Services AG500
进行中（未招募）
1 期
A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosisOnychomycosis (mild to moderate)MedDRA version: 8.1Level: LLTClassification code 10030338Term: OnychomycosisEUCTR2006-003506-25-ISovartis Pharma Services AG500
进行中（未招募）
不适用
A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome - NDBasal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma SyndromeMedDRA version: 12.1Level: LLTClassification code 10004146Term: Basal cell carcinomaEUCTR2010-019856-30-ITOVARTIS FARMA109
招募中
1 期
GuARD: GR1014 cutaneous gel Against Radiation DermatitisRadiation-induced dermatitis (radiodermatitis)MedDRA version: 24.1Level: LLTClassification code: 10061103Term: Dermatitis radiation Class: 10022117CTIS2023-508728-36-00Graegis Pharmaceuticals Limited273
进行中（未招募）
2 期
GuARD - GR1014 cutaneous gel Against Radiation DermatitisRadiodermatitis occurring with adjuvant radiotherapy for localised breast cancer after lumpectomySkin and Connective Tissue DiseasesISRCTN61697120Graegis Pharmaceuticals Ltd273